Versartis (VSAR) Stock Price, News & Analysis

Company Overview

Aravive, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX.

Key Stats

• Today's Range: $1.18 to $1.30
• 50-Day Range: $1.19 to $1.19
• 52-Week Range: $1.14 to $2.76
• Volume: 349,963 shs
• Average Volume: 479,436 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VSAR Stock Analysis - Frequently Asked Questions

How were Versartis' earnings last quarter?

Versartis, Inc. (NASDAQ:VSAR) issued its quarterly earnings data on Tuesday, August, 7th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.96) by $0.69.

What other stocks do shareholders of Versartis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Versartis investors own include Progenics Pharmaceuticals (PGNX), ZIOPHARM Oncology (ZIOP), Bausch Health Cos (BHC), Flexion Therapeutics (FLXN), Genocea Biosciences (GNCA), Novavax (NVAX) and Protalix BioTherapeutics (PLX).

Company Calendar

• Last Earnings: 8/07/2018
• Today: 8/23/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:VSAR
• CIK: 1513818
• Web: www.versartis.com
• Phone: (936) 355-1910
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Optionable
• Beta: N/A